Note: Descriptions are shown in the official language in which they were submitted.
JC05216USNP CA 2961868 2017-03-23
TOPICAL COMPOSITIONS CONTAINING CROSS-LINKED GLYCOSAMINOGLYCANS
Field of the Invention
The present invention provides topical compositions comprising cross-linked
sulfated glycosaminoglycans and methods of making and using the same for
treating skin,
for example for signs of skin aging.
Background of the Invention
Glycosaminoglycans, or GAG's, are naturally occurring, high molecular weight
polysaccharides. They are present in human cartilage, joint fluids, and skin
tissue. They
play roles in several biological processes in the body, such as moisturization
and
lubrication of tissues. Chondroitin sulfate, for example, is a sulfated
glycosaminoglycan
that is a copolymer of N-acetyl-D-galactosamine and D-glucuronic acid. It is
commonly
used to treat joint disorders as an oral supplement, injectable, or topical
cream. Heparan
sulfate, keratin sulfate and dermatan sulfate are other known sulfated
glycosaminoglycans.
It would be desirable to deliver chondroitin sulfate and other sulfated
glycosaminoglycans to treat cosmetic skin conditions, such as signs of aging
or dry skin, by
topical administration, which is convenient and painless. However, the stratum
corneum
of mammalian skin presents a formidable barrier to penetration. The ability of
a
substance to penetrate through the skin is inversely related to the thickness
of the
stratum corneum layer and the size of the substance. Large, polymeric
molecules are
difficult to administer topically. In addition, the negatively charged sulfate
groups of
sulfated glycosaminoglycans also reduce their skin penetration efficiencies.
Compositions and methods for the topical delivery of sulfated
glycosaminoglycans
in cross-linked, nanoparticle form have now been identified. Methods of
treating skin
using such compositions are also provided. Cross-linked sulfated
glycosaminoglycan
nanoparticles are capable of effective skin penetration alone or as a delivery
system for
other active agents.
Summary of the Invention
The present invention provides a topical composition comprising a cross-linked
sulfated glycosaminoglycan and a cosmetically acceptable topical carrier.
1
JC05216USNP CA 2961868 2017-03-23
The present invention also provides a topical composition comprising a
cosmetically acceptable active ingredient carried in a matrix comprising a
cross-linked
sulfated glycosaminoglycan and a cosmetically acceptable topical carrier.
The present invention further provides a method of treating signs of skin
aging,
comprising topically applying to skin in need of treatment for signs of skin
aging a topical
composition comprising a cross-linked sulfated glycosaminoglycan and a
cosmetically
acceptable topical carrier.
The invention also provides a method of moisturizing skin, comprising
topically
applying to skin in need of moisturization treatment a topical composition
comprising a
cross-linked sulfated glycosaminoglycan and a cosmetically acceptable topical
carrier.
Detailed Description of the Invention
Unless defined otherwise, all technical and scientific terms used herein have
the
same meaning as commonly understood by one of ordinary skill in the art to
which the
invention belongs. All publications, patent applications, patents, and other
references
mentioned herein are incorporated by reference.
As used herein, "topically applying" means directly laying on or spreading on
outer
skin, the scalp, or hair, e.g., by use of the hands or an applicator such as a
wipe, roller, or
spray.
As used herein, "cosmetically acceptable" means that the ingredients the term
describes are suitable for use in contact with tissues (e.g., the skin or
hair) without undue
toxicity, incompatibility, instability, irritation, allergic response, or the
like.
As used herein, a "cosmetically acceptable active agent" is a compound
(synthetic
or natural) that has a cosmetic or therapeutic effect on the skin or hair.
Compositions of the present invention are suitable for treating signs of skin
aging.
As used herein, "signs of skin aging" includes the presence of lines and
wrinkles, loss of
elasticity, uneven skin, and blotchiness. In a particularly preferred
embodiment, the sign
of aging is the presence of lines and wrinkles and/or loss of elasticity.
As used herein, "treating signs of skin aging" refers to mitigating, reducing,
preventing, improving, or eliminating the presence or signs of skin aging
described above.
As used herein, "wrinkle" includes fine lines, fine wrinkles, or coarse
wrinkles.
Examples of wrinkles include, but are not limited to, fine lines around the
eyes (e.g.,
2
JC05216USNP CA 2961868 2017-03-23
=
= "crow's feet"), forehead and cheek wrinkles, frown-lines, and laugh-lines
around the
mouth.
As used herein, "loss of elasticity" includes loss of elasticity or structural
integrity
of the skin or tissue, including but not limited to sagging, lax and loose
tissue. The loss of
elasticity or tissue structure integrity may be a result of a number of
factors, including but
not limited to disease, aging, hormonal changes, mechanical trauma,
environmental
damage, or the result of an application of products, such as a cosmetics or
pharmaceuticals, to the tissue.
As used herein, "uneven skin" means a condition of the skin associated with
diffuse or mottled pigmentation, which may be classified as hyperpigmentation,
such as
post-inflammatory hyperpigmentation.
As used herein, "blotchiness" means a condition of the skin associated with
redness or erythema.
As used herein, "cosmetic" refers to a beautifying substance or preparation
which
preserves, restores, bestows, simulates, or enhances the appearance of bodily
beauty or
appears to enhance the beauty or youthfulness, specifically as it relates to
the
appearance of tissue or skin.
As used herein, "cosmetically effective amount" means an amount of a
physiologically active compound or composition sufficient for treating one or
more signs
of skin aging, but low enough to avoid serious side effects. The cosmetically
effective
amount of the compound or composition will vary with the particular condition
being
treated, the age and physical condition of the end user, the severity of the
condition
being treated/prevented, the duration of the treatment, the nature of other
treatments,
the specific compound or product/composition employed, the particular
cosmetically-
acceptable carrier utilized, and like factors.
Compositions of the invention are also useful for treating skin in need of
nnoisturization. As used herein, "skin in need of moisturization" means a skin
that is, but
not limited to, lacking in moisture, lacking in sebum, cracked, dry, itchy,
scaly,
xerodermic, dehydrated, lacks suppleness, lacks radiance, dull, or lacks
lipids.
Unless otherwise indicated, a percentage or concentration refers to a
percentage
or concentration by weight (i.e., % (W/W). Unless stated otherwise, all ranges
are
inclusive of the endpoints, e.g., "from 4 to 9" includes the endpoints 4 and
9.
3
JC05216USNP CA 2961868 2017-03-23
Sulfated Glycosaminoglycans
The composition comprises one or more sulfated glycosaminoglycan which are
cross-linked according to the invention. The glycosaminoglycan substrates used
to create
the cross-linked sulfated glycosaminoglycan may be selected from the group
consisting of
chondroitin sulfate, heparan sulfate, dermatan sulfate, and keratan sulfate.
Mixtures of
the foregoing may be used.
The cross-linked sulfated glycosaminoglycan may be fully or partially cross-
linked.
A mixture of linear and cross-linked sulfated glycosaminoglycans may also be
used.
The sulfated glycosaminoglycan used to make the cross-linked sulfated
glycosaminoglycan may be obtained from animal sources or bacterial sources.
In one embodiment, the cross-linked sulfated glycosaminoglycan is cross-linked
chondroitin sulfate. The chondroitin sulfate may be animal-derived, such as
from salmon,
shark, bovine, or porcine origin. Animal-derived chondroitin sulfate is
commercially
available from Sigma Aldrich and other chemical suppliers.
In another embodiment, the chondroitin sulfate is bacterial-derived. Examples
of
bacterial-derived chondroitin sulfate include MYTHOCONDRO , commercially
available
from Gnosis S.p.A. Bacterial-derived chondroitin sulfate may be preferred as a
cosmetically acceptable ingredient because its use avoids animal use and
testing.
The cross-lined sulfated glycosaminoglycan is cross-linked with a monovalent,
divalent, or trivalent cation, or any cationic species comprising monovalent
or trivalent
ions. In one embodiment, the cross-linked sulfated glycosaminoglycan is cross-
linked
with an ion selected from the group consisting of calcium ions, strontium
ions, and
magnesium ions. In particular, the cross-linked sulfated glycosaminoglycan may
comprise
calcium ions.
The cross-linked sulfated glycosaminoglycan may be made by a variety of
methods. For example it may be made by drop-wise titration of a solution
containing the
desired ion into a solution of the sulfated glycosaminoglycan with continuous
mixing. The
sulfated glycosaminoglycan may be dissolved in water or phosphate buffered
saline. A
salt containing the desired ion is added in slowly with constant stirring
until a hazy
suspension is achieved.
The degree of cross-linking and particle size may be adjusted by controlling
the pH
of the mixture and the speed of mixing. As such, the cross-linking may be
altered by
4
JC05216USNP CA 2961868 2017-03-23
varying pH environment in use, such as with intradermal penetration. In one
embodiment, the particles uncross-link when the pH environment of the skin is
varied,
releasing contents of the particle to the skin.
In one embodiment, the cross-linked sulfated glycosaminoglycan is in the form
of
nanoparticles. In one embodiment the nanoparticles have a particle size of
about 100 nm
to about 10 m. In another embodiment, the nanoparticles have a particle size
of about
500 nm to about 5 p.m
In one embodiment, the topical composition comprises cross-linked sulfated
glycosaminoglycan as an active ingredient itself.
Cosmetically Acceptable Active Agents
Any cosmetically acceptable active agent may also be used in the composition.
It
may be loaded in the cross-linked sulfated glycosaminoglycan or present
separately in the
topical composition.
In a particular embodiment, the cosmetically acceptable active agent is loaded
into cross-linked sulfated glycosaminoglycan, which forms a polymer matrix.
This enables
the cross-linked chondroitin sulfate to function as a delivery system for the
active agent.
The cosmetically acceptable active agent may be loaded into the cross-linked
sulfated glycosaminoglycan by entrapment.
The cosmetically acceptable active agent may be loaded into the cross-linked
sulfated glycosaminoglycan by ionic binding.
In one embodiment, the cosmetically acceptable active agent may be a sulfate-
containing agent which is ionically cross linked with the chondroitin sulfate
polymer
matrix.
Without wishing to be bound by theory, it is believed that cross-linked
chondroitin
sulfate may assist in the delivery of cosmetically acceptable active agents
through the skin
and preferably follicular structures within the skin given the size range of
cross linked
particles. This size range is ideal for permeation into follicular appendages
and achieves
sustained release benefits over time.
Cosmetically acceptable active agents include for example anti-acne agents,
shine
control agents, anti-microbial agents, anti-inflammatory agents, anti-mycotic
agents, anti-
parasite agents, external analgesics, sunscreens, photoprotectors,
antioxidants,
5
JC05216USNP CA 2961868 2017-03-23
keratolytic agents, surfactants, moisturizers, nutrients, vitamins, energy
enhancers, anti-
perspiration agents, astringents, deodorants, firming agents, anti-callous
agents, agents
for hair and/or skin conditioning, and other glycosaminoglycans such as
hyaluronic acid.
The amount of cosmetically active agent in the composition may range from
about
0.001% to about 20% by weight of the composition, e.g., about 0.005% to about
10% by
weight of the composition, such as about 0.01% to about 5% by weight of the
composition.
The cosmetically acceptable active agent may be selected for instance from
hydroxy acids, benzoyl peroxide, D-panthenol carotenoids, retinoids such as
retinol and
retinyl palmitate, ceramides, polyunsaturated fatty acids, essential fatty
acids, enzymes
such as laccase, enzyme inhibitors, minerals, hormones such as estrogens,
steroids such
as hydrocortisone, 2-dimethylaminoethanol, copper salts such as copper
chloride,
peptides like argireline, syn-ake and those containing copper, coenzyme 010,
amino
acids such as proline, vitamins, lactobionic acid, acetyl-coenzyme A, niacin,
riboflavin,
thiamin, ribose, electron transporters such as NADH and FADH2, natural
extracts such as
from aloe vera, feverfew, oatmeal, dill, blackberry, princess tree,
resorcinols such as 4-
hexyl resorcinol, curcuminoids, and derivatives and mixtures thereof.
Examples of vitamins include, but are not limited to, vitamin A, vitamin B's
such as
vitamin B3, vitamin 65, and vitamin B12, vitamin C, vitamin K, and different
forms of
vitamin E like alpha, beta, gamma or delta tocopherols or their mixtures, and
derivatives
thereof.
Examples of hydroxy acids include, but are not limited, to glycolic acid,
lactic acid,
malic acid, salicylic acid, citric acid, and tartaric acid.
Examples of antioxidants include, but are not limited to, water-soluble
antioxidants such as sulfhydryl compounds and their derivatives (e.g., sodium
metabisulfite and N-acetyl-cysteine), lipoic acid and dihydrolipoic acid,
resveratrol,
lactoferrin, and ascorbic acid and ascorbic acid derivatives (e.g., ascorbyl
palmitate and
ascorbyl polypeptide). Oil-soluble antioxidants suitable for use in the
compositions of this
invention include, but are not limited to, butylated hydroxytoluene, retinoids
(e.g., retinol
and retinyl palmitate), tocopherols (e.g., tocopherol acetate), tocotrienols,
and
ubiquinone. Natural extracts containing antioxidants suitable for use in the
compositions
of this invention, include, but not limited to, extracts containing flavonoids
and
isoflavonoids and their derivatives (e.g., genistein and diadzein), extracts
containing
6
JC05216USNP CA 2961868 2017-03-23
resveratrol and the like. Examples of such natural extracts include grape
seed, green tea,
pine bark, and propolis.
Topical Compositions
The compositions of the present invention are applied topically to human skin
or
hair. Accordingly, the composition may further include a cosmetically
acceptable topical
carrier. The carrier may be from about 50% to about 99.99%, by weight, of the
composition (e.g., from about 80% to about 99%, by weight, of the
composition). In a
preferred embodiment of the invention, the cosmetically acceptable topical
carrier
includes water.
The compositions may be made into a wide variety of product types that include
but are not limited to lotions, creams, gels, sticks, sprays, ointments,
cleansing liquid
washes and solid bars, shampoos and hair conditioners, hair fixers, pastes,
foams,
powders, mousses, shaving creams, wipes, patches, hydrogels, film-forming
products,
facial masks and skin masks, films and make-up such as foundations, and
mascaras.
These product types may contain a variety of cosmetically acceptable topical
carriers
including, but not limited to solutions, suspensions, emulsions such as
microemulsions
and nanoemulsions, gels, solids and liposomes. The following are non-limiting
examples
of such carriers. Other carriers can be formulated by those of ordinary skill
in the art.
The compositions useful in the present invention can be formulated as
solutions.
Solutions typically include an aqueous or organic solvent (e.g., from about
50% to about
99.99% or from about 90% to about 99% of a cosmetically acceptable aqueous or
organic
solvent). Examples of suitable organic solvents include propylene glycol,
polyethylene
glycol, polypropylene glycol, glycerol, 1,2,4-butanetriol, sorbitol esters,
1,2,6-hexanetriol,
ethanol, and mixtures thereof.
Compositions useful in the subject invention may be formulated as a solution
comprising an emollient. Such compositions preferably contain from about 2% to
about
50% of an emollient(s). As used herein, "emollients" refer to materials used
for the
prevention or relief of dryness, such as by preventing the transepidermal loss
of water
from the skin. Examples of emollients include, but are not limited to, those
set forth in
the International Cosmetic Ingredient Dictionary and Handbook, eds. Pepe,
Wenninger
and McEwen, pp. 2930-36 (The Cosmetic, Toiletry, and Fragrance Assoc.,
Washington,
D.C., 9th Edition, 2002) (hereinafter "ICI Handbook"). Examples of
particularly suitable
emollients include vegetable oils, mineral oils, fatty esters, and the like.
7
JC05216USNP CA 2961868 2017-03-23
A lotion can be made from such a solution. Lotions typically contain from
about
1% to about 20% (e.g., from about 5% to about 10%) of an emollient(s) and from
about
50% to about 90% (e.g., from about 60% to about 80%) of water.
Another type of product that may be formulated from a solution is a cream. A
cream typically contains from about 5% to about 50% (e.g., from about 10% to
about
20%) of an emollient(s) and from about 45% to about 85% (e.g., from about 50%
to about
75%) of water.
The composition of the present invention may include water or alternatively be
anhydrous or be an ointment that includes no water but organic and/or silicone
solvents,
oils, lipids and waxes. An ointment may contain a simple base of animal or
vegetable oils
or semi-solid hydrocarbons. An ointment may contain from about 2% to about 10%
of an
emollient(s) plus from about 0.1% to about 2% of a thickening agent(s).
Examples of
thickening agents include, but are not limited to, those set forth in the ICI
Handbook pp.
2979-84.
The composition may be formulated as an emulsion. If the topical carrier is an
emulsion, from about 1% to about 10% (e.g., from about 2% to about 5%) of the
topical
carrier contains an emulsifier(s). Emulsifiers may be nonionic, anionic or
cationic.
Examples of emulsifiers include, but are not limited to, those set forth in
the ICI
Handbook, pp.2962-71.
Lotions and creams can be formulated as emulsions. Typically such lotions
contain
from 0.5% to about 5% of an emulsifier(s). Such creams typically contain from
about 1%
to about 20% (e.g., from about 5% to about 10%) of an emollient(s); from about
20% to
about 80% (e.g., from 30% to about 70%) of water; and from about 1% to about
10% (e.g.,
from about 2% to about 5%) of an emulsifier(s).
Single emulsion skin care preparations, such as lotions and creams, of the oil-
in-
water type and water-in-oil type are well-known in the cosmetic art and are
useful in the
subject invention. Multiphase emulsion compositions, such as the water-in-oil-
in-water
type or the oil-in-water-in-oil type, are also useful in the subject
invention. In general,
such single or multiphase emulsions contain water, emollients, and emulsifiers
as
essential ingredients.
The compositions of this invention can also be formulated as a gel (e.g., an
aqueous, alcohol, alcohol/water, or oil gel using a suitable gelling
agent(s)). Suitable
gelling agents for aqueous and/or alcoholic gels include, but are not limited
to, natural
gums, acrylic acid and acrylate polymers and copolymers, and cellulose
derivatives (e.g.,
8
JC05216USNP CA 2961868 2017-03-23
. hydroxymethyl cellulose and hydroxypropyl cellulose). Suitable
gelling agents for oils
(such as mineral oil) include, but are not limited to, hydrogenated
butylene/ethylene/styrene copolymer and hydrogenated
ethylene/propylene/styrene
copolymer. Such gels typically contains between about 0.1% and 5%, by weight,
of such
gelling agents.
The compositions of the present invention can also be formulated into a solid
formulation (e.g., a wax-based stick, soap bar composition, powder, or a wipe
containing
powder).
The compositions useful in the subject invention may contain, in addition to
the
aforementioned components, a wide variety of additional oil-soluble materials
and/or
water-soluble materials conventionally used in compositions for use on skin
and hair, at
their art-established levels.
Various other materials may also be present in the composition, as known in
the
art. These include hunnectants, pH adjusters, chelating agents (e.g., EDTA),
fragrances,
dyes, and preservatives (e.g., parabens).
The composition and formulations and products containing such compositions of
the present invention may be prepared using methodology that is well known by
an artisan
of ordinary skill.
In one embodiment, the topical composition comprises a cross-linked sulfated
glycosaminoglycan in an emulsion comprising an aqueous phase, oil phase, and
non-ionic
lipid phase.
The aqueous phase contains water.
The aqueous phase may also contain structuring agents such as carbomers or
other thickeners, for example, xanthan gum, carageenan gum, polyacrylate-13;
polyisobutene; polysorbate-20; polyacrylate-13/polyisobutylene/polysorbate-20
blends,
and the like including mixtures thereof.
Preferably, the composition comprises a thickener and the thickener is
hydroxyethyl acrylate/sodium acryloyldinnethyl taurate copolymer.
The oil phase contains at least one cosmetically-acceptable oil.
As used herein, the term "oil" means a hydrophobic material that can aid in
balancing the intermolecular forces to form micelle aggregates or to limit
their sizes. Oils
9
JC05216USNP CA 2961868 2017-03-23
also serve as emollient ingredients to benefit product spreadibility, skin
feel and delivery
of hydrophobic active ingredients such as but not limited to, Vitamins D, E, K
and A, and
sunscreen filters.
Oils that are useful in the composition include a variety of hydrocarbon-based
oils,
silicones, fatty acid derivatives, glycerides, vegetable oils, vegetable oil
derivatives, alkyl
esters, wax esters, beeswax derivatives, sterols, and phospholipids and
combinations
thereof ranging from approximately 20% to 50%, based on the total weight of
the
composition.
Suitable hydrocarbon oils include petrolatum, mineral oil, micro-crystalline
waxes,
squalene and combinations thereof.
Silicone oils include dimethicone, dimethiconol, phenyl dimethicone and cyclic
polysiloxanes and combinations thereof. Silicone oils having viscosities from
about 0.5 to
about 100,000 centistokes at 25 C. may also be useful in the composition.
Glycerides include castor oil, sunflower seed oil, coconut oil and
derivatives,
vegetable oils and derivatives, palm oil, jojoba oil, Shea butter, lanolin and
combinations
thereof.
Alkyl ester oils include, but are not limited to, isopropyl esters of fatty
acids and
esters of long chain fatty acids. More preferably, the following alkyl esters
are useful:
isopropyl palmitate, isopropyl myristate, myristyl myristate, isohexyl
palmitate, decyl
oleate, isononyl isononanoate and combinations thereof.
The non-ionic lipid phase comprises one or more non-ionic lipids, such as
glyceryl
monoesters having a fatty acid chain containing from about 3 to about 50
carbon atoms,
and preferably from about 10 to about 18 carbon atoms; glyceryl diesters
having a fatty
acid chain containing from about 5 carbon atoms to about 25 carbon atoms, and
preferably from about 10 carbon atoms to about 18 carbon atoms; alkoxylated
alcohols;
alkoxylated alkyl phenols; alkoxylated acids; alkoxylated amides; alkoxylated
sugar
derivatives; alkoxylated derivatives of natural oils or waxes; polyoxyethylene
polyoxypropylene block copolymers; polyoxyethylene ether fatty acids having a
fatty acid
chain containing from about 10 carbon atoms to about 18 carbon atoms;
steroids; fatty
acid esters of alcohols where the fatty acid is straight or branched chain
having from
about 10 carbon atoms to about 20 carbon atoms and the alcohol is straight or
branched
chain having 1 to 10 carbon atoms; and mixtures thereof, wherein the
alkoxylated lipids
are alkoxylated with ethylene oxide or propylene oxide, with ethylene oxide
being
preferred.
JC05216USNP CA 2961868 2017-03-23
= Examples of suitable glyceryl monoesters include, but are not limited to,
glyceryl
caprate, glyceryl caprylate, glyceryl cocate, glyceryl erucate, glyceryl
hydroxysterate,
glyceryl isostea rate, glyceryl lanolate, glyceryl laurate, glyceryl linolate,
glyceryl myristate,
glyceryl oleate, glyceryl PABA, glyceryl palmitate, glyceryl ricinoleate,
glyceryl stearate,
glyceryl thiglycolate, and mixtures thereof, with glyceryl laurate and
glyceryl myristate
being preferred.
Examples of suitable glyceryl diesters include, but are not limited to,
glyceryl
dilaurate, glyceryl dioleate, glyceryl dimyristate, glyceryl disterate,
glyceryl sesuioleate,
glyceryl stearate lactate, and mixtures thereof, with glyceryl dilaurate and
glyceryl
dimyristate being preferred.
Examples of suitable polyoxyethylene fatty ethers include, but are not limited
to,
polyoxyethylene cetyl/stearyl ether, polyoxyethylene cholesterol ether,
polyoxyethylene
laurate or dilaurate, polyoxyethylene stearate or distearate, polyoxyethylene
lauryl or
stearyl ether, and mixtures thereof, wherein the polyoxyethylene head group
ranges from
about 2 to about 100 groups. Preferred polyoxyethylene fatty ethers include
polyoxyethylene stearyl ether, polyoxyethylene myristyl ether, and
polyoxyethylene
lauryl ether having from about 3 to about 10 oxyethylene units.
Examples of suitable steroids include, but are not limited to, cholesterol,
betasitosterol, bisabolol, and mixtures thereof.
Examples of suitable fatty acid esters of alcohols include isopropyl
myristate,
aliphati-isopropyl n-butyrate, isopropyl n-hexanoate, isopropyl n-decanoate,
isoproppyl
palmitate, octyidodecyl myristate.
Exemplary alkoxylated alcohols useful as the nonionic lipid in the
compositions of
the invention have the structure shown in Formula I below:
R5--(OCH2CH2)y--OH Formula I
wherein R5 is a branched or unbranched alkyl group having from about 6 to
about 22
carbon atoms and y is between about 4 and about 100, and preferably, between
about 10
and about 100. A preferred alkoxylated alcohol is the species wherein R5 is a
lauryl group
and y has an average value of 23, which is known as laureth 23 and is
available from ICI
Americas, Inc. of Wilmington, Del. under the tradename "BRIJ 35."
Another exemplary alkoxylated alcohol is an ethoxylated derivative of lanolin
alcohol. Lanolin alcohol is a mixture of organic alcohols obtained from the
hydrolysis of
11
JC05216USNP CA 2961868 2017-03-23
. lanolin. An example of an ethoxylated derivative of lanolin alcohol
is laneth-10, which is
the polyethylene glycol ether of lanolin alcohol with an average ethoxylation
value of 10.
Another exemplary alkoxylated alcohol is polyoxypropylene polyoxyethylene
alkyl
ether, for example PPG-12-Buteth-16. This material is available from Amerchol
Corp. of
Edison, N.J. under the tradename, "UCON Fluid 50-HB-660."
Another type of non-ionic lipids includes alkoxylated alkyl phenols, for
example
nonoxyno1-14"and is available under the tradename, "MAKON 14" from the Stepan
Company of Northfield, Ill.
Another type of non-ionic lipids is alkoxylated acids, which are esters of an
acid,
most usually a fatty acid, with a polyalkylene glycol, for example PEG-8
laurate.
Another type of non-ionic lipids includes alkoxylated amides, for example PEG-
6
cocoamide.
Another type of non-ionic lipids includes the alkoxylated sugar derivatives,
for
instance polysorbate 20, a mixture of laurate esters of sorbitol and sorbitol
anhydrides,
consisting predominately of the monoester, condensed with about 20 moles of
ethylene
oxide. This material is available under the tradename "TWEEN 20" from ICI
Americas of
Wilmington, Del.
Another example of an alkoxylated sugar derivative useful in the compositions
of
the invention is PEG-20 methylglucose sesquistearate, which is the
polyethyleneglycol
ether of the sesquiester of methyl glucose and stearic acid, contains an
average of 20
moles of ethylene oxide, and is available under the tradename, "GLUCAMATE SSE-
20"
from the Amerchol Corp. of Edison, N.J.
Another type of non-ionic lipids includes the alkoxylated derivatives of
natural oils
and waxes. Examples of this class of material include PEG-40 lanolin, PEG-40
castor oil
and PEG-40 hydrogenated castor oil.
Another type of non-ionic lipids includes polyoxyethylene polyoxypropylene
block
copolymers, for example Poloxamer 101 and Poloxamer 182.
Preferred nonionic lipids include polyoxyethylene fatty ethers, glyceryl
diesters,
and mixtures thereof. More preferred nonionic lipids include polyoxyethylene
stearyl
ether, polyoxyethylene myristyl ether, and polyoxyethylene lauryl ether,
glyceryl
dilaurate, glyceryl dimystate, glyceryl distearate, and mixtures thereof,
whereby each
ether has from about 5 to about 10 oxyethylene units.
12
JC05216USNP CA 2961868 2017-03-23
In an embodiment wherein the reduction of skin irritation is a concern, it is
preferable to use a nonionic lipid having a greater amount of carbon atoms on
the
hydrophilic head group moiety, or in the alternative, a nonionic lipid having
a greater
amount of carbon atoms on the hydrophobic fatty acid chain moiety. The former
can be
achieved by increasing the amount of carbon atoms on the head group of, for
example, a
polyoxyethylene-10-stearyl ether from about 10 carbon atoms to from about 15
to 20
carbon atoms. The latter can be achieved by increasing the amount of carbon
atoms on
the 12 carbon fatty acid tail of, for example, glyceryl diesters to from about
14 carbons to
about 16 carbons.
The composition of the present invention includes, based upon the total weight
of
the composition, from about 1 percent to about 10 percent, and preferably from
about 3
percent to about 7 percent of the nonionic lipid.
In a preferred embodiment, the non-ionic lipid phase comprises water,
glyceride
dilaurate, steareth-10, and glycerin.
In one embodiment the composition comprises chondroitin sulfate, lactic acid,
steareth 10, glycerol dilaurate, and glycerin. The chondroitin sulfate may be
linear
chondroitin sulfate. The chondroitin sulfate may be cross-linked chondroitin
sulfate. The
chondroitin sulfate may be a mixture of linear and cross-linked chondroitin
sulfate.
pH
In one embodiment, the topical composition has a low pH. For example, the pH
may be less than about 4 or less than about 3.3.
The topical composition may comprise a buffering agent such as lactic acid,
glycolic acid, citric acid, malic acid, tartaric acid, gluconic acid, or
gluconolactone.
Preferably the buffering agent is lactic acid.
Typically, the composition contains about 3 to about 12, or about 4 to about
8,
weight percent of buffering agent.
Methods of Treating Skin
According to the invention signs of skin aging may be treated by topically
applying
to skin in need of treatment for signs of skin aging a topical composition
comprising a
cross-linked sulfated glycosaminoglycan and a cosmetically acceptable topical
carrier.
13
JC05216USNP CA 2961868 2017-03-23
In addition, skin may be moisturized by topically applying to skin in need of
moisturization treatment a topical composition comprising a cross-linked
sulfated
glycosaminoglycan and a cosmetically acceptable topical carrier.
The following non-limiting examples further illustrate the invention.
Example 1
Samples of cross-linked chondroitin sulfate were made according to the
invention
as follows.
Each of bovine trachea-derived and bacterial-derived chondroitin sulfate (CS)
was
used at the following amounts: 0.4%, 1.1%, 3.3% and 10% w/v. The bovine
trachea-
derived CS was obtained from Sigma-Aldrich. The bacteria-derived CS was
obtained from
Gnosis S.p.A.
The samples of chondroitin sulfate were dissolved in water or phosphate
buffered
saline (PBS) to produce 10 ml solutions. Then 10.1 M calcium chloride solution
was added
dropwise to each sample with stirring at 0.18 grams/gram of chondroitin
sulfate. (For
example for the 3.3% CS 10 ml solution, 40.8 ul of 10.1 M calcium chloride
solution was
added.) Samples made using CS in the PBS vehicle resulted in hazy suspensions
(due to
the ions on PBS), while the samples made using CS in water remained clear.
The resulting suspensions were analyzed by SEM for the presence of
nanoparticles. Electron microscopy images confirmed the presence of particles
in all
samples. However, the samples made in PBS resulted in more particles than the
samples
made in water.
Solutions of linear chondroitin sulfate starting material in both the vehicles
were
also evaluated by SEM. In the absence of a positively charged ion, no
nanoparticles
formed and the solutions were clear compared to the hazy suspensions formed
due to
the presence of Ca2+.
Additional samples were made by adding all the CaCl2 solution in one step.
This
resulted in larger, micron-sized aggregates of the particles, also confirmed
by SEM.
Example 2
In vitro skin penetration of linear and calcium cross-linked chondroitin
sulfate
using the samples listed in Table 1 below was measured as follows.
Chondroitin sulfate was obtained from Gnosis S.p.A.
14
JC05216USNP CA 2961868 2017-03-23
=
= = Cross-linked chondroitin sulfate was made as described in
Example 1 using PBS as
the vehicle. PBS solution served as the control.
The penetration tests were performed using human epidermal equivalent tissues
(MatTek Corporation, EpiDerm-Epi-200). The epidermal equivalent tissues were
handled
and cultured following the vendor's instructions. Prior to testing the well
plates
containing the EpiDerm tissue samples were equilibrated in a humidified 37 C,
5% CO2
incubator for 24 hours. Then for each sample, 50 ul of sample was topically
applied on
tissue, and then incubated in culture for 48 hours.
Culture media underneath the tissue samples were collected 48 hours post-
treatment and measured for chondroitin sulfate volume using HPAEC-PAD assay
after
Trifluoroacetic Acid (TFA) hydrolysis.
The results are shown in Table 1.
JC05216USNP CA 2961868 2017-03-23
4
TABLE 1
SAMPLE PENETRATION (Mg-L)
Untreated 1.7
PBS (Control) 0
0.4% Gnosis CS in PBS (Comparative) 5
1.1% Gnosis CS in PBS (Comparative) 29.2
3.3% Gnosis CS in PBS (Comparative) 334.5
10%Gnosis CS in PBS (Comparative) 516
0.4% Gnosis CS in PBS+CaCl2 9.7
1.1% Gnosis CS in PBS+CaCl2 18.6
3.3% Gnosis CS in PBS+CaCl2 249.5
10% Gnosis CS in PBS+CaCl2 332.5
16
